FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 317:1049-1054 October 22, 1987 Number 17 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We undertook a prospective randomized trial to examine whether an intravenous cytomegalovirus (CMV) immune globulin would prevent primary CMV disease in renal-transplant recipients. Fifty-nine CMV-seronegative patients who received kidneys from donors who had antibodies against CMV were assigned to receive either intravenous CMV immune globulin or no treatment. The immune globulin was administered in multiple doses over the first four months after transplantation. The incidence of virologically confirmed CMV-associated syndromes was reduced from 60 percent in controls to 21 percent in recipients of CMV immune globulin (P less than 0.01). Fungal or parasitic superinfections were not seen in globulin recipients but occurred in 20 percent of controls (P = 0.05). Only 4 percent of globulin recipients had marked leukopenia (reflecting serious CMV disease), as compared with 37 percent of the controls (P less than 0.01). There was a concomitant but not statistically significant reduction in the incidence of CMV pneumonia (17 percent of controls as compared with 4 percent of globulin recipients). A significant reduction in serious CMV-associated disease was observed even when patients were stratified according to therapy for transplant rejection (P = 0.04). We observed no effect of immune globulin on rates of viral isolation or seroconversion, suggesting that treated patients often harbored the virus but that clinically evident disease was much less likely to develop in them. We conclude that CMV immune globulin provides effective prophylaxis in renal-transplant recipients at risk for primary CMV disease.

Source Information

Department of Medicine, Brigham and Women's Hospital, Boston, MA 02111.

This article has been cited by other articles:

• van Stijn, A., Rowshani, A. T., Yong, S. L., Baas, F., Roosnek, E., ten Berge, I. J. M., van Lier, R. A. W. (2008). Human Cytomegalovirus Infection Induces a Rapid and Sustained Change in the Expression of NK Cell Receptors on CD8+ T Cells. J. Immunol. 180: 4550-4560 [Abstract] [Full Text]  
• Weikert, B. C., Blumberg, E. A. (2008). Viral Infection after Renal Transplantation: Surveillance and Management. CJASN 3: S76-S86 [Abstract] [Full Text]  
• Reap, E. A., Dryga, S. A., Morris, J., Rivers, B., Norberg, P. K., Olmsted, R. A., Chulay, J. D. (2007). Cellular and Humoral Immune Responses to Alphavirus Replicon Vaccines Expressing Cytomegalovirus pp65, IE1, and gB Proteins. CVI 14: 748-755 [Abstract] [Full Text]  
• Adler, S. P., Marshall, B. (2007). Cytomegalovirus Infections. Pediatr. Rev. 28: 92-100 [Full Text]  
• Tan, B. H. (2006). CMV prophylaxis--to do or not to do, that is the question. Nephrol Dial Transplant 21: 1757-1761 [Full Text]  
• Nigro, G., Adler, S. P., La Torre, R., Best, A. M., the Congenital Cytomegalovirus Collaborating Group, (2005). Passive immunization during pregnancy for congenital cytomegalovirus infection.. NEJM 353: 1350-1362 [Abstract] [Full Text]  
• Bethea, B. T., Yuh, D. D., Conte, J. V., Baumgartner, W. A. (2003). Heart Transplantation. Card Surg Adult 2: 1427-1460 [Full Text]  
• Brumble, L. M., Milstone, A. P., Loyd, J. E., Ely, E. W., Pierson, R. N. III, Gautam, S., Dummer, J. S. (2002). Prevention of Cytomegalovirus Infection and Disease After Lung Transplantation : Results Using a Unique Regimen Employing Delayed Ganciclovir. Chest 121: 407-414 [Abstract] [Full Text]  
• Verrier, F., Nadas, A., Gorny, M. K., Zolla-Pazner, S. (2001). Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6. J. Virol. 75: 9177-9186 [Abstract] [Full Text]  
• Hemming, V. G. (2001). Use of Intravenous Immunoglobulins for Prophylaxis or Treatment of Infectious Diseases. CVI 8: 859-863 [Full Text]  
• BRENNAN, D. C. (2001). Cytomegalovirus in Renal Transplantation. J. Am. Soc. Nephrol. 12: 848-855 [Full Text]  
• Keller, M. A., Stiehm, E. R. (2000). Passive Immunity in Prevention and Treatment of Infectious Diseases. Clin. Microbiol. Rev. 13: 602-614 [Abstract] [Full Text]  
• (2000). Management of herpes virus infections following transplantation. J Antimicrob Chemother 45: 729-748 [Full Text]  
• ter Meulen, C. G., Wetzels, J. F. M., Hilbrands, L. B. (2000). The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation. Nephrol Dial Transplant 15: 711-714 [Abstract] [Full Text]  
• Sia, I. G., Patel, R. (2000). New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients. Clin. Microbiol. Rev. 13: 83-121 [Abstract] [Full Text]  
• Shapiro, M. E., Abrams, J. M., Lowance, D., Keating, M. R. (1999). Valacyclovir to Prevent Cytomegalovirus Disease after Renal Transplantation. NEJM 341: 921-921 [Full Text]  
• Mascola, J. R., Lewis, M. G., Stiegler, G., Harris, D., VanCott, T. C., Hayes, D., Louder, M. K., Brown, C. R., Sapan, C. V., Frankel, S. S., Lu, Y., Robb, M. L., Katinger, H., Birx, D. L. (1999). Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies. J. Virol. 73: 4009-4018 [Abstract] [Full Text]  
• Gigliotti, F., Wiley, J. A., Harmsen, A. G. (1998). Immunization with Pneumocystis carinii gpA Is Immunogenic but Not Protective in a Mouse Model of P. carinii Pneumonia. Infect. Immun. 66: 3179-3182 [Abstract] [Full Text]  
• Wechsler, M. E., Giardina, E.-G. V., Sciacca, R. R., Rose, E. A., Barr, M. L. (1995). Increased Early Mortality in Women Undergoing Cardiac Transplantation. Circulation 91: 1029-1035 [Abstract] [Full Text]